MARLBOROUGH, Mass.,
June 8, 2017 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics that address significant
unmet medical needs, announced today that its President and CEO,
Dr. Geert Cauwenbergh will present
at the Marcum MicroCap Conference being held in New York City. Dr. Cauwenbergh will present a
corporate overview that includes its proprietary self-delivering
RNA (sd-rxRNA®) therapeutic platform and the Company's ongoing
research and clinical programs in cell-based immunotherapy,
dermatology, and ophthalmology.
This event provides a platform for smaller entrepreneurial
public companies with less than $500M
in market capitalization to present to and meet with institutional
investors, venture and lower middle-market private equity investors
and buy- and sell-side analysts. The conference is being held
on June 15-16, 2017 at the Grand
Hyatt Hotel in NYC.
- RXi Pharmaceuticals presentation at the Marcum MicroCap
Conference
June 15, 2017 at 4:00pm ET, Morosco Room
Geert Cauwenbergh, Dr. Med. Sc.,
President and CEO, RXi Pharmaceuticals
The presentation will be available under the "Investors – Events
and Presentations" section of the Company's website,
www.rxipharma.com approximately 1 hour following the
presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA)
Technology Platform
Building on the pioneering discovery of RNAi, scientists at RXi
have harnessed the naturally occurring RNAi process which has the
ability to "silence" or down-regulate the expression of a specific
gene that may be overexpressed in a disease condition. The Company
developed a robust RNAi therapeutic platform that includes
self-delivering RNAi (sd-rxRNA) compounds that have the ability to
highly selectively block the expression of any target in the
genome, thus providing applicability to a broad spectrum of
therapeutic areas. This proprietary sd-rxRNA technology has many
advantages over its competitors in the RNAi space because of
built-in delivery properties and no requirement of a delivery
vehicle for local therapeutic applications. sd-rxRNA
compounds are chemically-modified RNAi compounds with improved
drug-like properties that are potent, stable and specific.
The enhanced properties of sd-rxRNA include: efficient
spontaneous cellular uptake, stability, reduced potential for
immune stimulation, and potent, long-lasting intracellular
activity. All cell types tested (primary, neuronal and
non-adherent) internalize sd-rxRNA compounds uniformly and
efficiently, resulting in potent and long lasting silencing.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the pioneering
discovery of RNAi, scientists at RXi have harnessed the naturally
occurring RNAi process which has the ability to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust RNAi
therapeutic platform including self-delivering RNA (sd-rxRNA)
compounds that have the ability to highly selectively block the
expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology and cell-based immunotherapy.
RXi's extensive patent portfolio provides for multiple product and
business development opportunities across a broad spectrum of
therapeutic areas and we actively pursue research collaborations,
partnering and out-licensing opportunities with academia and
pharmaceutical companies. Additional information may be found on
the Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and to not
act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-marcum-microcap-conference-300470833.html
SOURCE RXi Pharmaceuticals Corporation